• CDC
  • Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Screening
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

Heart Failure Milestones in Management: 9 Studies Making a Difference in 2021

Slideshow

SGLT-2 inhibitors have proven effective in disease modification as well as symptom improvement across HF phenotypes and severity. Get a quick summary of the research.

Sodium-glucose cotransporter-2 (SGLT-2) inhibitors have proven effective in disease modification and symptom improvement across heart failure (HF) phenotypes and severity with results of recent landmark clinical trials laying groundwork for FDA approval and updates to clinical practice guidelines.

Other findings released in 2021 shed light on factors that both worsen and improve HF-associated morbidity and mortality. Highlights of 9 notable studies follow in the slide show below.

Related Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
Where Should SGLT-2 Inhibitor Therapy Begin? Thoughts from Drs Mikhail Kosiborod and Neil Skolnik
Related Content
FDA Expands Indication for RSV Vaccine Abrysvo to Include Adults Aged 18 to 59 with Chronic Conditions

FDA Expands Indication for RSV Vaccine Abrysvo to Include Adults Aged 18 to 59 with Chronic Conditions

Grace Halsey
October 23rd 2024
Article

Pfizer announced the FDA approval on October 22 that makes Abrysvo now the RSV immunization with the broadest indication for adults, the company said.

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

Sydney Jennings
August 30th 2023
Podcast

Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.

FDA Grants Priority Review to GSK NDA for First-In-Class Oral Antibiotic / Image credit: ©sopradit/AdobeStock

FDA Grants Priority Review to GSK NDA for First-In-Class Oral Antibiotic

Sydney Jennings
October 16th 2024
Article

The FDA today accepted GSK's NDA for gepotidacin for the treatment of uncomplicated urinary tract infections in women and adolescents.

Primary Viewpoints Episode 4: Lp(a): The Next CVD Target?

Primary Viewpoints Episode 4: Lp(a): The Next CVD Target?

Patient Care Editorial Staff
October 29th 2020
Podcast

Patrick Moriarty, MD, from the University of Kansas Medical Center, discusses the role of Lp(a) as a risk factor for cardiovascular disease and the phase 3 trials of a potential treatment.

FDA Faces Law Suit Over Sudden Removal of Tirzepatide from Drug Shortage List / image credit Mounjaro: ©MK Photo/stock.adobe.com

FDA Faces Law Suit Over Sudden Removal of Tirzepatide from Drug Shortage List

Ashley Gallagher;Grace Halsey
October 15th 2024
Article

Update: The FDA has told compounding pharmacies they may resume production of tirzepatide products while the agency further investigates supply.

COVID-19 Linked to Long-Term Risk of MACE, Especially Among Adults with non-O Blood Types

COVID-19 Linked to Long-Term Risk of MACE, Especially Among Adults with non-O Blood Types

Sydney Jennings
October 9th 2024
Article

Prior SARS-CoV-2 infection was associated with a 2-fold increased risk for MACE for up to 3 years, even among people with no history of CVD, in a new analysis of UK Biobank data.

© 2024 MJH Life Sciences

All rights reserved.